Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

NCT05172258 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05172258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05172258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 26, 2022
Completion date
June 30, 2027
Enrollment
52 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, metastatic head and neck squamous cell carcinoma, metastatic hypopharyngeal squamous cell carcinoma, metastatic laryngeal squamous cell carcinoma, metastatic oral cavity squamous cell carcinoma, metastatic oropharyngeal squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, stage iv hypopharyngeal carcinoma ajcc v8, stage iv laryngeal cancer ajcc v8, stage iv lip and oral cavity cancer ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8